Search the Newsreel

DBV Technologies (NASDAQ:DBVT) Stock Price Up 8.4% - Time to Buy?

DBV Technologies SA (DBV.HM) options chain

This article provides the options chain information for DBV Technologies SA (DBV.HM) on Yahoo Finance. It displays a summary of the stock's performance, showing its closing price and percentage change. The options chain section indicates that there are currently no calls or puts available …

DBV Technologies SA (DBV.HM) stock price, news, quote and history

This article provides detailed financial information for DBV Technologies SA (DBV.HM), including its current stock price, historical data, performance metrics, and key financial highlights. It shows the stock trading at 2.3280 EUR with a 2.28% increase at market close, alongside comparisons to the CAC …

Arrowstreet Capital discloses net short position in DBV Technologies

Arrowstreet Capital has reported a 0.6% net short position in DBV Technologies. This information was generated by Public Technologies (PUBT) using AI, based on original content published by DBV Technologies SA. The article includes disclaimers noting that the content is for informational purposes only …

DBV Technologies SA (DBV.HM) valuation measures and financial statistics

Dbv Technologies SA (DBVT) Stock News Today

RA Capital discloses DBV Technologies (DBVT) 5.8% ownership via ADS holding

RA Capital Management, L.P., along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., has reported a 5.8% beneficial ownership in DBV Technologies S.A. The group collectively owns 18,288,220 ordinary shares, held through 3,657,644 American Depositary Shares (ADSs), with each ADS representing …

DBV Technologies stock rebounds 2.5% with RSI in oversold territory at 29

DBV Technologies stock gained 2.42% to €2.37, ranking among the strongest gains of the SBF 120, despite being down nearly 18% over one month and more than 29% over three months. The stock's rebound from its €2.31 support level and an RSI of 29 …

Perceptive Advisors LLC Invests $20.15 Million in DBV Technologies S.A. $DBVT

DBV Technologies (DBVT) CMO sells shares to cover RSU taxes

DBV Technologies' Chief Medical Officer, Mohideen Pharis, sold 464 ordinary shares at $2.70 per share on July 29, 2026. This transaction was executed to cover withholding tax obligations arising from the vesting of restricted stock units. After the sale, Pharis directly holds 144,531 ordinary …

DBV - Pediatric Peanut Allergy Treatment Pipeline Will Support A Long-Term Bullish Thesis

DBV Technologies, a biopharmaceutical company, is positioned for a potential revenue-generating commercial model with its Viaskin Peanut immunotherapy patch for pediatric peanut allergy. Analysts project significant revenue growth and a shift to profitability, driven by a stable addressable market and ongoing clinical program expansion. …

DBV Technologies S.A. $DBVT Shares Acquired by Vivo Capital LLC

DBV Technologies raises $50M via At-The-Market ADS placement on Nasdaq to fund allergy treatment development.

DBV Technologies has successfully raised $50 million through an At-The-Market (ATM) offering of American Depositary Shares (ADS) on Nasdaq. This funding, achieved by issuing 3.66 million ADS at $13.67 each, will bolster the company's financial standing and support the advanced development of its VIASKIN® …

DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq

DBV Technologies announced it has sold approximately $50 million worth of American Depositary Shares (ADSs) through its At-The-Market (ATM) program on Nasdaq. This transaction was conducted between July 1, 2026, and July 31, 2026, utilizing its existing prospectus supplement. The company stated this strategic …

DBV Technologies sells USD 50 million ADSs to RA Capital via Nasdaq ATM program

DBV Technologies completed a private placement, selling 3,657,644 ADSs to RA Capital for approximately $50 million gross through its Nasdaq at-the-market program. This transaction, priced at $13.67 per ADS, represents a 0.15% discount to the prior Euronext Paris close and will result in about …

ADAR1 Capital Management LLC Acquires New Shares in DBV Technologies S.A. $DBVT

Dbv Technologies SA (DBVT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Dbv Technologies SA (DBVT), including stock price information and market capitalization. However, it explicitly states that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. Consequently, …

DBV Technologies (Nasdaq: DBVT) sets up broad shelf to issue shares, ADSs and warrants

DBV Technologies (Nasdaq: DBVT) has filed an automatic shelf registration statement on Form S-3, allowing it to issue an indeterminate amount of ordinary shares, ADSs, and warrants. This permits the company and selling security holders to conduct offerings flexibly, with net proceeds from DBV's …

Form S-3ASR DBV TECHNOLOGIES S.A. For: 27 July By Investing.com

DBV Technologies rated Buy after positive Phase 3 results for peanut allergy patch Viaskin.

DBV Technologies received a Buy rating after its Viaskin Peanut patch showed positive Phase 3 trial results for desensitizing children with peanut allergies. An analyst's valuation model suggests a fair value of $42 per ADS, projecting strong market uptake and a temporary revenue peak …

DBV Technologies: Regulatory Noise, Commercial Misperception, And A Deep Valuation Gap

Dbv Technologies SA (DBVT) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed overview of Dbv Technologies SA (DBVT)'s shareholder structure, including major shareholders, institutional holdings, and recent shareholder activity. Key entities like Vivo Capital, Artisan Partners, and Invus Public Equities Advisors are listed with their respective proportions. The report also tracks …

DBVT Options Chain — NASDAQ:DBVT

This article provides an options chain overview for DBV Technologies S.A. (NASDAQ: DBVT) on TradingView. It details how users can track market movements, evaluate risks, and monitor live pricing, Greeks, and implied volatility for available call and put options. The options chain is a …

DBV Technologies rated buy with 24% upside as Viaskin nears FDA submission in Q3 2026.

DBV Technologies, a biotech company developing the Viaskin dermal patch for peanut allergies, has received a "buy" rating with a 24% upside potential to a $17 price target by FY 2027. This positive outlook is driven by the anticipated Biologics License Application (BLA) submission …

DBV Technologies on Track for Lowest Close Since December 2025 -- Data Talk

DBV Technologies is on track to close at its lowest point since December 2025. This downturn in stock performance is a significant event for the company, indicating potential concerns for investors.

We Think DBV Technologies (EPA:DBV) Needs To Drive Business Growth Carefully

DBV Technologies, a clinical-stage biopharmaceutical company, had a cash burn of US$171 million over the last year, with cash reserves of US$175 million as of June 2026, giving it a runway of approximately 12 months. While its cash burn increased by 93%, operating revenue …

DBV Technologies (NASDAQ:DBVT) Sees Large Volume Increase - Should You Buy?

DBV Technologies stock falls on $150M share offering plan

DBV Technologies' stock fell by 3.7% after the biopharmaceutical company announced a refresh of its "at-the-market" offering program, allowing it to sell up to $150 million in American Depositary Shares. The company intends to use the net proceeds for manufacturing expansion, biologics license applications, …

Weekly Recap: VIASKIN Peanut BLA Q3 2026 and H1 2026 $98M loss, $174.9M

DBV Technologies SA (NASDAQ: DBVT) is progressing its VIASKIN Peanut program, aiming for a BLA submission with priority review in Q3 2026. Despite a $98M net loss in H1 2026, the company holds $174.9M in cash, assuring funding through Q3 2027. This recap highlights …

DBV Technologies Raises $150M for Peanut Allergy Patch

DBV Technologies has secured an additional $150 million through an at-the-market equity facility to support the imminent Biologics License Application (BLA) for its VIASKIN Peanut Patch. The funds will be used for manufacturing expansion, BLA-related activities, and launch preparations for the 4-7-year-old population. This …

DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales

DBV Technologies has filed an automatically effective shelf registration statement with the U.S. SEC, including a prospectus supplement to refresh its At-The-Market (ATM) offering program. This allows for the sale of up to $150 million of American Depositary Shares (ADS) to fund manufacturing expansion, …

DBV Technologies Plans Viaskin Peanut Launch Prep, If Approved

DBV Technologies has refiled an at-the-market (ATM) offering program for up to $150 million of American Depositary Shares (ADSs) to fund manufacturing expansion, BLA activities, and potential launch preparation for Viaskin Peanut in ages 4-7, if approved. The program allows for flexible financing, though …

Cantor Fitzgerald reiterates Overweight on DBV Technologies stock

Cantor Fitzgerald has reiterated an Overweight rating and a $48.00 price target for DBV Technologies (NASDAQ: DBVT), indicating a potential upside of over 220%. The company recently completed recruitment for its COMFORT Toddlers study and plans to submit a Biologics License Application for children …